Medisearch Clinical Trials

1. Novartis Pharmaceuticals Corporation $811,523 13 payments
2. AbbVie, Inc. $610,714 153 payments
3. Incyte Corporation $492,076 384 payments
4. Aclaris Therapeutics, Inc. $254,844 25 payments
5. Pfizer Inc. $243,051 113 payments
6. Amgen Inc. $86,557 12 payments
7. E.R. Squibb & Sons, L.L.C. $80,480 6 payments
8. Arcutis Biotherapeutics, Inc. $72,012 25 payments
9. Horizon Therapeutics plc $49,559 2 payments
10. Perrigo Company plc $39,515 3 payments

1. A Randomized Double Blind Multicenter Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of Subcutaneous Secukinumab in Subjects of Body Weight 90 KG Or Higher With Moderate to Severe Chronic Plaque Type Psoriasis $678,898 2 payments
2. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy $236,261 43 payments
3. A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice A Week in Subjects With Common Warts $228,875 16 payments
4. A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Prurigo Nodularis $173,409 138 payments
5. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $114,067 34 payments
6. A Randomized Double Blind Multi Center Study Assessing Short 16 Weeks and Long Term Efficacy Up to 1 Year Safety and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa Sunshine $78,876 5 payments
7. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis $52,922 16 payments
8. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis $51,543 11 payments
9. Phase 2AB Safety and Efficacy Study of Pf06700841 in Patients With Moderate Psoriasis $48,199 21 payments
10. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Investigate the Efficacy and Safety of Daxdilimab Subcutaneous Injection in Reducing Disease Activity in Adult Participants With Moderate-To-Severe Primary Discoid Lupus Erythematosus $47,511 1 payment

1. Professional salary support $16,800 3 payments
2. Patient care $5,500 1 payment
3. Overhead $4,500 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.